Poor prognosis and advanced clinicopathological features of clear cell renal cell carcinoma (ccRCC) are associated with cytoplasmic subcellular localisation of Hypoxia inducible factor-2α

European Journal of Cancer

Volumn 50, Issue 8, 2014, Pages 1531-1540

  Kroeger, Nils ^a,b   Seligson, David B ^c   Signoretti, Sabina ^d   Yu, Hong ^c   Magyar, Clara E ^c   Huang, Jiaoti ^c   Belldegrun, Arie S ^a   Pantuck, Allan J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

CA IX; Cancer specific survival; HIF 1; HIF 2; mTOR; Renal cell carcinoma; Tumour promotor; Tumour suppressor; VEGF

Indexed keywords

CARBONATE DEHYDRATASE IX; HYPOXIA INDUCIBLE FACTOR 2ALPHA; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 3;

ADULT; ADVANCED CANCER; ANTIGEN RETRIEVAL; ARTICLE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SIZE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CLINICAL FEATURE; CONTROLLED STUDY; CYTOPLASM; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TRANSLATION INITIATION;

CA-IX; CANCER SPECIFIC SURVIVAL; HIF-1; HIF-2; MTOR; RENAL CELL CARCINOMA; TUMOUR PROMOTOR; TUMOUR SUPPRESSOR; VEGF;

AGED; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CALIFORNIA; CARCINOMA, RENAL CELL; CYTOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS;

EID: 84898865980     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.01.031     Document Type: Article

References (25)

1. L. Li, and W.G. Kaelin Jr. New insights into the biology of renal cell carcinoma Hematol Oncol Clin North Am 25 4 2011 667 686
2. J.D. Gordan, P. Lal, V.R. Dondeti, R. Letrero, K.N. Parekh, and C.E. Oquendo et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma Cancer Cell 14 6 2008 435 446
3. K. Kondo, W.Y. Kim, M. Lechpammer, and W.G. Kaelin Jr. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth PLoS Biol 1 3 2003 E83
4. J.K. Maranchie, J.R. Vasselli, J. Riss, J.S. Bonifacino, W.M. Linehan, and R.D. Klausner The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma Cancer Cell 1 3 2002 247 255 (Pubitemid 41039149)
5. R.R. Raval, K.W. Lau, M.G.B. Tran, H.M. Sowter, S.J. Mandriota, and J.L. Li et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma Mol Cell Biol 25 13 2005 5675 5686 (Pubitemid 40853601)
6. J. Uniacke, C.E. Holterman, G. Lachance, A. Franovic, M.D. Jacob, and M.R. Fabian et al. An oxygen-regulated switch in the protein synthesis machinery Nature 486 7401 2012 126 129
7. M.M. Oken, R.H. Creech, D.C. Tormey, J. Horton, T.E. Davis, and E.T. McFadden et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 6 1982 649 655 (Pubitemid 13149996)
8. M. Gerlinger, A.J. Rowan, S. Horswell, J. Larkin, D. Endesfelder, and E. Gronroos et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N Engl J Med 366 10 2012 883 892
9. B.Y. Zhang, R.H. Thompson, C.M. Lohse, R.S. Dronca, J.C. Cheville, and E.D. Kwon et al. Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up BJU Int 111 7 2013 1046 1053
10. T. Klatte, D.B. Seligson, J. LaRochelle, B. Shuch, J.W. Said, and S.B. Riggs et al. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy Cancer Epidemiol Biomarkers Prev 18 3 2009 894 900
11. A.J. Pantuck, D.B. Seligson, T. Klatte, H. Yu, J.T. Leppert, and L. Moore et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy Cancer 109 11 2007 2257 2267 (Pubitemid 46801555)
12. N. Ferrara, H.P. Gerber, and J. LeCouter The biology of VEGF and its receptors Nat Med 9 6 2003 669 676 (Pubitemid 36749215)
13. M.J. Karkkainen, and T.V. Petrova Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis Oncogene 19 49 2000 5598 5605
14. S.A. Stacker, C. Caesar, M.E. Baldwin, G.E. Thornton, R.A. Williams, and R. Prevo et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics Nat Med 7 2 2001 186 191 (Pubitemid 32148485)
15. C. Shen, R. Beroukhim, S.E. Schumacher, J. Zhou, M. Chang, and S. Signoretti et al. Genetic and functional studies implicate HIF1alpha as a 14q kidney cancer suppressor gene Cancer Discov 1 3 2011 222 235
16. N. Kroeger, T. Klatte, K. Chamie, P.N. Rao, F.D. Birkhauser, and G.A. Sonn et al. Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma Cancer 119 8 2013 1547 1554
17. H. Van Poppel, F. Becker, J.A. Cadeddu, I.S. Gill, G. Janetschek, and M.A. Jewett et al. Treatment of localised renal cell carcinoma Eur Urol 60 4 2011 662 672
18. A.J. Pantuck, A. Zisman, F. Dorey, D.H. Chao, K.R. Han, and J. Said et al. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy Cancer 97 12 2003 2995 3002 (Pubitemid 36676253)
19. N. Kroeger, D.B. Seligson, T. Klatte, E.N. Rampersaud, F.D. Birkhauser, and P.N. Rao et al. Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma Eur Urol 61 5 2012 888 895
20. M. Atkins, M. Regan, D. McDermott, J. Mier, E. Stanbridge, and A. Youmans et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer Clin Cancer Res 11 10 2005 3714 3721 (Pubitemid 40685588)
21. M.H. Bui, D. Seligson, K.R. Han, A.J. Pantuck, F.J. Dorey, and Y. Huang et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy Clin Cancer Res 9 2 2003 802 811 (Pubitemid 36182618)
22. B.C. Leibovich, Y. Sheinin, C.M. Lohse, R.H. Thompson, J.C. Cheville, and J. Zavada et al. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma J Clin Oncol 25 30 2007 4757 4764 (Pubitemid 350086478)
23. B.Y. Zhang, R.H. Thompson, C.M. Lohse, R.S. Dronca, J.C. Cheville, and E.D. Kwon et al. Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up BJU Int 111 7 2013 1046 1053
24. B. Shuch, G. Bratslavsky, W.M. Linehan, and R. Srinivasan Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies Oncologist 17 1 2012 46 54
25. A. Zisman, A.J. Pantuck, F. Dorey, J.W. Said, O. Shvarts, and D. Quintana et al. Improved prognostication of renal cell carcinoma using an integrated staging system J Clin Oncol 19 6 2001 1649 1657 (Pubitemid 32230864)